EXPERT LOGIN
__________________
The Cytonet Group is an international biotechnology company with locations in Weinheim and Heidelberg in Germany and in Durham, North Carolina in the U.S. The company develops, produces and markets cell therapeutic products, including human liver cells.  Cytonet’s goal is to  provide alternatives to existing therapies for many diseases with a particular emphasis on liver diseases.   Cytonet is a pioneer and leader in the field of regenerative medicine. Through the development of novel approaches to treatment we are helping to shape the future of medicine.


  • Liver cell therapy can reduce incidence and severity of hyperammonemic crises in infants with urea cycle disorders
    Cytonet presents current study findings on the occasion of the annual meeting of the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2015 Weinheim/Lyon, September ...  read on

  • First baby patient in Canada to receive liver cell therapy
    A three-months old girl became the first patient in Canada to receive liver cell therapy, an experimental and potentially life-saving procedure from Cytonet LLC, to improve the ...  read on

  • FIRST DATA ON CYONET’S LIVER CELL THERAPY FOR UREA CYCLE DISORDERS PRESENTED AT THE ANNUAL MEETING OF THE SOCIETY FOR INHERITED METABOLIC DISORDERS (SIMD)
    Weinheim, Germany and Raleigh-Durham, NC, March 10, 2014 – Interim data on the use of liver cell therapy (LCT) for the treatment of pediatric patients with Urea ...  read on

  • CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
    Weinheim/Germany, January, 2014 – International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its ...  read on

  • HOME PRESS CONTACT MEDIA VIDEOS CONTACT PRIVACY POLICY IMPRINT